This inventor holds 1 USPTO granted patent. Top assignee: Biotie Therapies Corporation. Active years: 2004.
Company Filing History:
Years Active: 2004
Title: Innovations of Jing-ping Li in Glucuronyl C5-epimerase Research
Introduction
Jing-ping Li is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of biochemistry, particularly in the area of glucuronyl C5-epimerase research. His work has implications for understanding and manipulating glycosaminoglycan biosynthesis.
Latest Patents
Jing-ping Li holds a patent for a DNA sequence encoding a novel glucuronyl C5-epimerase. This patent describes an isolated or recombinant DNA sequence coding for a mammalian, including human, glucuronyl C5-epimerase or a functional derivative capable of converting D-glucuronyl acid (GlcA) to L-iduronic acid (IdoA). The patent also includes a recombinant expression vector comprising such DNA sequence, a host cell transformed with the recombinant expression vector, and a process for manufacturing a glucuronyl C5-epimerase or functional derivative capable of converting GlcA to IdoA. This process involves the cultivation of a cell line transformed with the recombinant expression vector, leading to the production of the glucuronyl C5-epimerase or its functional derivatives.
Career Highlights
Jing-ping Li is associated with Biotie Therapies Corporation, where he has been involved in innovative research and development. His work has contributed to advancements in therapeutic applications and biotechnological processes.
Collaborations
Jing-ping Li collaborates with Ulf Lindahl, enhancing the research efforts in their field. Their partnership has fostered a productive environment for scientific exploration and innovation.
Conclusion
Jing-ping Li's contributions to the field of glucuronyl C5-epimerase research exemplify the impact of innovative thinking in biotechnology. His patent and collaborative efforts continue to advance our understanding of biochemical processes.